Publications by authors named "Elizabeth Schackmann"
CEBPB copy number gain in Ewing sarcoma was previously shown to be associated with worse clinical outcome compared to tumors with normal CEBPB copy number, although the mechanism was not characterized. We employed gene knockdown and rescue assays to explore the consequences of altered CEBPB gene expression in Ewing sarcoma cell lines. Knockdown of EWS-FLI1 expression led to a decrease in expression of all three C/EBPβ isoforms while re-expression of EWS-FLI1 rescued C/EBPβ expression.
View Article and Find Full Text PDFArticle Synopsis
- * A study (PrECOG 0105) evaluated this resistance mechanism among newly diagnosed patients with -mutant breast cancer who did not respond well to platinum-based therapy.
- * The study found that among 19 mutation carriers, one patient developed a reversion mutation during therapy, which may have led to poor treatment outcomes, early relapse, and eventual death from metastatic breast cancer.
Phase II Study of Gemcitabine, Carboplatin, and Iniparib As Neoadjuvant Therapy for Triple-Negative and BRCA1/2 Mutation-Associated Breast Cancer With Assessment of a Tumor-Based Measure of Genomic Instability: PrECOG 0105.
J Clin Oncol
June 2015
Article Synopsis
- - The study evaluated the effectiveness and safety of iniparib combined with gemcitabine and carboplatin in treating early-stage triple-negative and BRCA1/2 mutation-associated breast cancer.
- - Involved 80 patients, with a 36% overall pathologic complete response rate, indicating a significant impact of the treatment.
- - The results revealed that patients with higher homologous recombination deficiency (HRD-LOH) scores had better responses, suggesting HRD-LOH could help identify effective treatment candidates even among those without BRCA mutations.
Pre-clinical and epidemiologic studies provide rationale for evaluating lipophilic statins for breast cancer prevention. We conducted a single-arm, biomarker modulation trial of lovastatin among women with increased risk of breast cancer. Eligibility criteria included a deleterious germline mutation in BRCA1, BRCA2, CDH1, or TP53; lifetime breast cancer risk of ≥20 % as estimated by the Claus model; or personal history of estrogen receptor and progesterone receptor-negative breast cancer.
View Article and Find Full Text PDFWomen with BRCA1 or BRCA2 (BRCA1/2) mutations face difficult decisions about managing their high risks of breast and ovarian cancer. We developed an online tool to guide decisions about cancer risk reduction (available at: http://brcatool.stanford.
View Article and Find Full Text PDFThe prevalence and penetrance of BRCA1 and BRCA2 (BRCA1/2) mutations may differ between Asians and whites. We investigated BRCA1/2 mutations and cancer risk factors in a clinic-based sample. BRCA1/2 mutation carriers were enrolled from cancer genetics clinics in Hong Kong and California according to standardized entry criteria.
View Article and Find Full Text PDFPurpose: Women with BRCA1 or BRCA2 (BRCA1/2) mutations must choose between prophylactic surgeries and screening to manage their high risks of breast and ovarian cancer, comparing options in terms of cancer incidence, survival, and quality of life. A clinical decision tool could guide these complex choices.
Methods: We built a Monte Carlo model for BRCA1/2 mutation carriers, simulating breast screening with annual mammography plus magnetic resonance imaging (MRI) from ages 25 to 69 years and prophylactic mastectomy (PM) and/or prophylactic oophorectomy (PO) at various ages.